img215675602_0.jpg 

 

7800 Rancharrah Parkway

 

Reno, NV 89511

 

PH (775) 788-2200 | FX (775) 786-1177

 

fennemorecraig.com

 

 

 

 

Exhibit 5.1

 

April 13, 2022

 

 

Kintara Therapeutics, Inc.

9920 Pacific Heights Blvd., Suite 150

San Diego, CA 92121

 

 

Re: Report on Form 8-K for Kintara Therapeutics, Inc.
 

Ladies and Gentlemen:

We are acting as special Nevada counsel to Kintara Therapeutics, Inc., a Nevada corporation (the “Company”), in connection with the filing of a report on Form 8-K with respect to the sale by the Company of (i) 16,226,416 shares (the “Shares”) of the Company’s common stock, $0.001 par value per share (“Common Stock”), (ii) warrants (the “Issued Warrants”) to purchase up to 16,226,416 shares of Common Stock (the “Issued Warrant Shares”) to be issued pursuant to the terms of the Securities Purchase Agreement, as defined below and (iii) placement agent warrants (the “Placement Agent Warrants”, and together with the Issued Warrants, the “Warrants”) to purchase 811,321 shares of Common Stock in a registered direct offering (the “Placement Warrant Shares”, and together with the Issued Warrant Shares, the “Warrant Shares”) to be issued to A.G.P./Alliance Global Partners ("Placement Agent") pursuant to the Agent Agreement, as defined below. Capitalized terms used herein and not otherwise defined shall have the meanings set forth in the Securities Purchase Agreement.

For the purpose of rendering this opinion, we have examined originals, or copies certified or otherwise identified to our satisfaction as being true copies, of such records, documents, instruments and certificates as, in our judgment, are necessary or appropriate to enable us to render the opinions set forth below, including, but not limited to, the following:

A. The Securities Purchase Agreement dated April 12, 2022 between the Company and the Purchasers named therein (the “Securities Purchase Agreement”);

B. The Agreement between the Company and the Placement Agent dated April 12, 2022 (the "Placement Agent Agreement");

C. The Warrants;

20326240.1/045223.0001


img215675602_1.jpg 

 

April 13, 2022

Page 2

 

 

D. The Articles of Incorporation and Bylaws of the Company, each as amended to date (collectively, the “Governing Documents”); and

E. Such corporate records and proceedings, minutes, consents, actions and resolutions of the board of directors as we have deemed necessary as a basis for the opinions expressed below.

We have made such legal and factual examinations and inquiries as we have deemed necessary or appropriate for the purposes of this opinion. We have also obtained from officers and agents of the Company and from public officials, and have relied upon, such certificates, representations and assurances as we have deemed necessary and appropriate for the purpose of rendering this opinion.

Without limiting the generality of the foregoing, in our examination, we have, with your permission, assumed without independent verification, that (i) all documents submitted to us as originals are authentic, the signatures on all documents that we examined are genuine, and all documents submitted to us as certified, conformed, photostatic, electronic or facsimile copies conform to the original document; and (ii) all corporate records made available to us by the Company and all public records we have reviewed are accurate and complete. We note that the Company has reserved, and assume it will continue to maintain reserved, a sufficient number of shares of its duly authorized, but unissued, shares of the Company’s Common Stock as is necessary to provide for the issuance of the Shares and the Warrant Shares.

Nothing herein shall be deemed an opinion as to the laws of any jurisdiction other than the state of Nevada. We express no opinion concerning any securities law or rule.

Based on the foregoing, and in reliance thereon, we are of the opinion that:

1. The Shares, the Warrants, and the Warrant Shares have been duly authorized by the Company for issuance and sale to the Purchasers in accordance with the Securities Purchase Agreement and the Placement Agent Agreement, as applicable.

2. When issued and delivered to the Purchasers by the Company in accordance with the Securities Purchase Agreement against payment by the Purchasers of the consideration set forth in the Securities Purchase Agreement, the Issued Warrants, will be validly issued, and the Shares and, upon exercise in accordance with the terms of the Issued Warrants, including payment of the exercise price therefor, if any, the Issued Warrant Shares, will be validly issued, fully paid and non-assessable.

3. When delivered in accordance with the terms of the Placement Agent Agreement Letter, the Placement Agent Warrants, will be validly issued, and the Placement Warrant Shares, upon exercise in accordance with the terms of the Placement Agent Warrants, including payment of the

20326240.1/045223.0001


img215675602_1.jpg 

 

April 13, 2022

Page 3

 

 

exercise price therefor, if any, the Placement Warrant Shares, will be validly issued, fully paid and non-assessable.

This opinion is issued in the State of Nevada. By issuing this opinion, Fennemore Craig, P.C. (i) shall not be deemed to be transacting business in any other state or jurisdiction other than the State of Nevada and (ii) does not consent to the jurisdiction of any state other than the State of Nevada. Any claim or cause of action arising out of the opinions expressed herein must be brought in the State of Nevada. Your acceptance of this opinion shall constitute your agreement to the foregoing.

We consent to your filing this opinion as an exhibit to the Registration Statement and to the reference to our firm contained under the heading “Legal Matters.” We further consent to the incorporation by reference of this opinion and consent in any registration statement filed pursuant to Rule 462(b) under the Act with respect to the Securities. In giving these consents, we do not thereby admit that we are within the category of persons whose consent is required under Section 7 of the Act, the rules and regulations of the Commission promulgated thereunder, or Item 509 of Regulation S-K. This opinion letter is rendered as of the date first written above and we disclaim any obligation to advise you of facts, circumstances, events or developments which hereafter may be brought to our attention and which may alter, affect or modify the opinion expressed herein. Our opinion is expressly limited to the matters set forth above and we render no opinion, whether by implication or otherwise, as to any other matters relating to the Company or the Securities.

Very truly yours,

 

 

/s/ Fennemore Craig, P.C.

 

Fennemore Craig, P.C.

 

CDOL

 

20326240.1/045223.0001